Sermorelin
Nudges your body to make a little more of its own growth hormone, taken as a nightly shot.
- What it is
- A daily shot that copies a natural growth-hormone signal called GHRH
- Is it FDA-approved?
- It was (as Geref), but it was pulled in 2008. Now made by compounding pharmacies
- How strong is the proof?
- Decent for kids with low growth hormone. Weak for adult anti-aging
- How you take it
- A small shot under the skin, usually at night
- Typical result
- IGF-1 (a growth marker) goes up about 30-60% over 3 months
- Biggest catch
- Banned in tested sports. Pre-mixed mail-order vials are often too weak
Any word with a dotted underline is a science word — tap it for a plain-English meaning.
In plain words.
Sermorelin is a you inject. It is the first 29 building blocks of a natural hormone called GHRH.
GHRH is the signal your brain sends to tell a gland (the pituitary) to release growth hormone. Sermorelin copies that signal. So instead of giving you growth hormone directly, it asks your body to make a bit more of its own.
It used to be under the name Geref. It was pulled from the market in 2008. That was a money decision, not a safety problem. Today you mostly get it from compounding pharmacies.
One thing to know: sermorelin breaks down fast once it is mixed. Its is only about 10-20 minutes in the body.
What people use it for.
Doctors first used it to help children who did not make enough growth hormone.
Now adults mostly use it off-label for "anti-aging" and energy. The idea is to raise growth hormone gently as you get older.
It is not as strong as taking real growth hormone (HGH). If you expect HGH-level results, this is weaker.
Does it actually work?
It works in the sense that it raises your . That is a blood marker that goes up when growth hormone goes up. In adults, IGF-1 climbs about 30-60% over 3 months.
The catch is what that actually does for you. The kid studies are solid. But the adult "anti-aging" studies are small and not strong. We do not have good proof it makes healthy adults feel or look better.
So the lab number moves. The real-life payoff is the part that is not proven.
what you’ve probably heard.
The claims floating around online, and how true they actually are.
“It gives you the benefits of HGH without the risks.”
not quiteIt is weaker than real growth hormone, and it works by asking your body to make a bit more of its own. Your does climb about 30 to 60% in 3 months, but it still raises that same growth signal, so the cancer caution does not go away.
“It is a legit anti-aging shot that makes you feel younger.”
unprovenThe lab number moves, but that is not the same as a payoff. The studies in kids with low growth hormone are solid; the adult anti-aging studies are small and weak. We do not have good proof it makes a healthy adult look or feel better.
“You can just take it once a week.”
noSermorelin clears your body in about 10 to 20 minutes. Weekly dosing cannot work on a molecule that short. A clinic selling weekly sermorelin is almost always shipping a different molecule.
“Mail-order pre-mixed vials are fine and save you the hassle.”
mythIt breaks down fast once it is mixed. Pre-mixed vials are usually weak by the time they reach you. The fix is to buy the freeze-dried powder, mix it yourself, and use it within about a week.
How you take it.
You take it as a small shot under the skin, usually at night. People do this because growth hormone naturally pulses while you sleep.
It comes as a (freeze-dried) powder. You mix it yourself with . This is called .
Because it breaks down fast, you should mix it yourself and use it within about 7 days kept in the fridge. Do not buy it pre-mixed by mail. Those vials are often weak by the time they reach you.
If a clinic sells you "weekly sermorelin," something is off. Sermorelin cannot work weekly. Its is too short. That label usually means it is a different molecule.
What to watch out for.
The common stuff
Most people tolerate it. You may get redness or itching where you inject. Some feel flushing or a headache.
The serious stuff
- It is banned by WADA. Do not use it if you compete in a tested sport.
- It raises , a growth signal. Do not use it if you have active or recent cancer.
- If you have real growth hormone deficiency, ask your doctor about regular growth hormone (somatropin) first.
If you run it, a doctor should check your over time. Talk to a real doctor. We are not your doctor.
Where people get it.
Here are the ways people get it, from safest to riskiest.
- Brand (Geref). Not available. It was discontinued in 2008.
- . Made by special pharmacies with a prescription. This is the main legal channel. About $150-$400 a month. Some clinics mark it up to $500-$900 by bundling consults and labs. Ask for the plain pharmacy price.
- Research-only (). Sold "for research only." Cheap, about $30-$100 a month. Higher risk. Vendors sometimes ship a different molecule (CJC-1295 or Mod GRF 1-29) by mistake.
- . Overseas raw powder, about $10-$25 a month. Same source as , no oversight.
Whatever lane you pick, ask for a . That is a lab report showing what is in the vial.
Our honest take.
Sermorelin has more human history than its cousins like CJC-1295 or Ipamorelin. But the adult anti-aging case is still thin.
We would not run it as a do-it-yourself anti-aging . If you had real, lab-confirmed growth hormone deficiency, we would ask an endocrinologist about regular growth hormone first.
If cost ruled that out, then sermorelin under a doctor, with checks, is reasonable. Ask the pharmacy how fresh the vial is. A weak, old vial is the most common way people waste their money here.
The studies behind this.
We read the research so you don't have to. Here's where the facts on this page come from.
- 01Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
- 02Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical interventions in aging. 2006;1(4):307-8. PMID: 18046908.
- 03Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug testing and analysis. 2021;13(11-12):1871-1887. PMID: 34665524.
- 04Chang Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of translational medicine. 2021;9(5):406. PMID: 33842627.
- 05Prakash A, et al. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 1999;12(2):139-57. PMID: 18031173.
- 06Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
- 07Cristea CD, et al. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Analytical biochemistry. 2023;682:115336. PMID: 37806509.
- 08González-López NM, et al. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomedical chromatography : BMC. 2023;37(12):e5741. PMID: 37688464.
- 09Otin J, et al. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis. Electrophoresis. 2023;44(9-10):807-817. PMID: 36787346.
- 10Gesmundo I, et al. Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells. International journal of molecular sciences. 2025;26(7). PMID: 40244089.
- 11Coppieters G, et al. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. Journal of pharmaceutical and biomedical analysis. 2022;214:114726. PMID: 35298973.
- 12Thomas A, et al. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of mass spectrometry : JMS. 2024;59(1):e4996. PMID: 38197510.
- 13Esposito P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Advanced drug delivery reviews. 2003;55(10):1279-91. PMID: 14499707.
- 14Grossman A, et al. Growth hormone releasing hormone. Clinics in endocrinology and metabolism. 1986;15(3):607-27. PMID: 2429796.
- 15Barkan A. When the light turns blue. Endocrinology. 1997;138(11):4527-9. PMID: 9348173.
- 16Knoop A, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and bioanalytical chemistry. 2016;408(12):3145-53. PMID: 26879649.
- 17Barabutis N. A glimpse at growth hormone-releasing hormone cosmos. Clinical and experimental pharmacology & physiology. 2020;47(9):1632-1634. PMID: 32289177.
- 18Louzada RA, et al. GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(25):e2209810120. PMID: 37307472.
- 19Thomas A, et al. Probing for peptidic drugs (2-10 kDa) in doping control blood samples. Analytical science advances. 2022;3(7-8):235-243. PMID: 38716080.
- 20Xu Y, et al. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. The Journal of international medical research. 2012;40(4):1217-26. PMID: 22971474.
- 21Uçaktürk E, et al. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2026;268:117207. PMID: 41138283.
- 22de Zegher F, et al. Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. The Journal of clinical endocrinology and metabolism. 1990;71(2):520-2. PMID: 2143200.
- 23Costoya J, et al. A novel approach for the treatment of AML, through GHRH antagonism: MIA-602. Reviews in endocrine & metabolic disorders. 2025;26(3):483-491. PMID: 39417961.
- 24Venhuis BJ, et al. Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. Drug testing and analysis. 2016;8(3-4):398-401. PMID: 26456392.
- 25Thomas A, et al. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug testing and analysis. 2015;7(11-12):990-8. PMID: 26382721.
- 26Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639.
- 27Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. PMID: 41880199.
- 28Byrnes ME. Reversed-phase high-performance liquid chromatography. A semipreparative methodology. Methods in molecular biology (Clifton, N.J.). 1994;36:37-52. PMID: 7535163.
- 29Muñoz-Moreno L, et al. Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH). The Prostate. 2022;82(8):933-941. PMID: 35322894.
- 30Sigalos JT, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health. 2017;11(6):1752-1757. PMID: 28830317.
- 31Belavgeni A, et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(44):22269-22274. PMID: 31611400.
- 32Cai R, et al. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides. 2022;150:170716. PMID: 34952135.
- 33Liang WC, et al. Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(11):6067-6074. PMID: 32123064.
- 34Pont L, et al. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. Journal of chromatography. A. 2020;1631:461548. PMID: 32971474.
- 35Muñoz-Moreno L, et al. Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers. International journal of molecular sciences. 2024;25(20). PMID: 39456984.
- 36Gaumond SI, et al. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia. Oncotarget. 2024;15:248-254. PMID: 38588464.
- 37Condor Capcha JM, et al. Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(48):e2308342120. PMID: 37983492.
- 38Recinella L, et al. Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice. Peptides. 2021;142:170582. PMID: 34051291.
- 39Wu HM, et al. Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro†. Biology of reproduction. 2022;106(1):145-154. PMID: 34792103.
- 40Rieger AC, et al. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(4). PMID: 33468654.
- 41Recinella L, et al. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Scientific reports. 2020;10(1):732. PMID: 31959947.
- 42Granato G, et al. Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells. Frontiers in immunology. 2023;14:1231363. PMID: 37649486.
- 43Zhang C, et al. Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin. Lung. 2019;197(5):541-549. PMID: 31392398.
- 44Muñoz-Moreno L, et al. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. The Prostate. 2018;78(12):915-926. PMID: 29748961.
- 45Rodrigues-Dos-Santos K, et al. Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress. Molecular and cellular endocrinology. 2021;535:111379. PMID: 34252492.
- 46Cervini LA, et al. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. Journal of medicinal chemistry. 1998;41(5):717-27. PMID: 9513600.
- 47Barabutis N, et al. GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2020;52(5):336-339. PMID: 32403147.
- 48Xiong X, et al. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(12):6726-6732. PMID: 32156725.
- 49Chu WK, et al. Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(50):14396-14401. PMID: 27911838.
- 50Lance VA, et al. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochemical and biophysical research communications. 1984;119(1):265-72. PMID: 6231028.
- 51Qin YJ, et al. Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(51):18303-8. PMID: 25489106.
- 52Sigdel M, et al. Growth hormone - releasing hormone antagonists induce autophagy in cancer cells. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2025;82:101668. PMID: 41075421.
- 53Gan J, et al. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(51):14745-14750. PMID: 27930339.
- 54Qin YJ, et al. Induction of Apoptosis in Pterygium Cells by Antagonists of Growth Hormone-Releasing Hormone Receptors. Investigative ophthalmology & visual science. 2018;59(12):5060-5066. PMID: 30357400.
- 55Thounaojam MC, et al. Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(50):13248-13253. PMID: 29180438.
- 56Ross RJ, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet (London, England). 1987;1(8523):5-8. PMID: 2879138.
- 57Cen LP, et al. Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(28). PMID: 34244423.
- 58Recinella L, et al. Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD. Molecular psychiatry. 2021;26(12):7465-7474. PMID: 34331008.
- 59Neyzi O, et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:16-21; discussion 22. PMID: 8329826.
- 60Wang H, et al. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone. International journal of cancer. 2018;142(11):2394-2404. PMID: 29435973.
Learn about these too.
We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.
Want the rest of the peptide world, in plain English?
New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.